{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:39:27Z","timestamp":1779377967450,"version":"3.53.1"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Endoceutics"},{"name":"Palatin Technologies"},{"name":"Alkermes"},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Forest"},{"name":"Marriott Foundation"},{"name":"Medibio Limited"},{"name":"Myriad"},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Naurex"},{"name":"Orexigen Therapeutics"},{"name":"Shire"},{"DOI":"10.13039\/100009655","name":"Sunovion Pharmaceuticals Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda Pharmaceutical"},{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Axsome Therapeutics"},{"name":"Endoceutics"},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Palatin Technologies"},{"name":"Sage Therapeutics"},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Valeant Pharmaceuticals North America"},{"name":"Sprout Pharmaceuticals"},{"name":"Valeant Pharmaceuticals North America"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.sxmr.2018.12.003","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T17:35:06Z","timestamp":1550943306000},"page":"380-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of Flibanserin Safety: Comparison with Other Serotonergic Medications"],"prefix":"10.1093","volume":"7","author":[{"given":"Sheryl A.","family":"Kingsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"McElroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita H.","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2018.12.003_bib1","series-title":"Diagnostic and statistical manual of mental disorders","year":"2000"},{"key":"10.1016\/j.sxmr.2018.12.003_bib2","series-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"10.1016\/j.sxmr.2018.12.003_bib3","first-page":"135","article-title":"Definitions of sexual dysfunctions in women and men: A consensus statement from the Fourth International Consultation on Sexual Medicine 2015","volume":"13","author":"McCabe","year":"2016","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib4","first-page":"1888","article-title":"Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions\u2014part II","volume":"13","author":"Parish","year":"2016","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mayocp.2016.09.018","article-title":"Hypoactive sexual desire disorder: International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review","volume":"92","author":"Goldstein","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.sxmr.2018.12.003_bib6","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/AOG.0b013e3181898cdb","article-title":"Sexual problems and distress in United States women: Prevalence and correlates","volume":"112","author":"Shifren","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/archinte.168.13.1441","article-title":"Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women","volume":"168","author":"West","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib8","first-page":"36","article-title":"Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1)","volume":"10","author":"Bitzer","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib9","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/GME.0000000000000131","article-title":"Hypoactive sexual desire in women","volume":"20","author":"Kingsberg","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.sxmr.2018.12.003_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijgo.2010.02.014","article-title":"The pathophysiology of hypoactive sexual desire disorder in women","volume":"110","author":"Clayton","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.sxmr.2018.12.003_bib11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-015-0288-1","article-title":"The female sexual response: Current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder","volume":"29","author":"Kingsberg","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sxmr.2018.12.003_bib12","first-page":"1506","article-title":"Pathways of sexual desire","volume":"6","author":"Pfaus","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4088\/JCP.10bs06115whi","article-title":"Circuits of sexual desire in hypoactive sexual desire disorder","volume":"71","author":"Stahl","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.sxmr.2018.12.003_bib14","first-page":"3449","article-title":"Flibanserin: Initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder","volume":"7","author":"Kennedy","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib15","series-title":"Addyi\u00ae (flibanserin) tablets [package insert]","year":"2018"},{"key":"10.1016\/j.sxmr.2018.12.003_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJMp1513686","article-title":"FDA approval of flibanserin\u2014treating hypoactive sexual desire disorder","volume":"374","author":"Joffe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1527-3458.2002.tb00219.x","article-title":"Pharmacology of flibanserin","volume":"8","author":"Borsini","year":"2002","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.sxmr.2018.12.003_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S1461145702002869","article-title":"Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain","volume":"5","author":"Marazziti","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib19","first-page":"1757","article-title":"Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: A microdialysis study","volume":"7","author":"Allers","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib20","first-page":"15","article-title":"Multifunctional pharmacology of flibanserin: Possible mechanism of therapeutic action in hypoactive sexual desire disorder","volume":"8","author":"Stahl","year":"2011","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib21","first-page":"1074","article-title":"Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the VIOLET study","volume":"9","author":"Derogatis","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib22","first-page":"793","article-title":"Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the DAISY study","volume":"9","author":"Thorp","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib23","first-page":"1807","article-title":"Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial","volume":"10","author":"Katz","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib24","first-page":"3160","article-title":"Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): Results from a randomized withdrawal trial","volume":"8","author":"Goldfischer","year":"2011","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/GME.0000000000000134","article-title":"Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: Results of the SNOWDROP trial","volume":"21","author":"Simon","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.sxmr.2018.12.003_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/009262300278597","article-title":"The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function","volume":"26","author":"Rosen","year":"2000","journal-title":"J\u00a0Sex Marital Ther"},{"key":"10.1016\/j.sxmr.2018.12.003_bib27","first-page":"357","article-title":"Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder","volume":"5","author":"Derogatis","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/AOG.0000000000000620","article-title":"Female sexual dysfunction: Focus on low desire","volume":"125","author":"Kingsberg","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852914000832","article-title":"Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder","volume":"20","author":"Stahl","year":"2015","journal-title":"CNS Spectr"},{"key":"10.1016\/j.sxmr.2018.12.003_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0165-0327(98)00221-3","article-title":"Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects","volume":"51","author":"Stahl","year":"1998","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.sxmr.2018.12.003_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4236\/ojd.2013.24011","article-title":"A\u00a0review of the serotonin-norepinephrine reuptake inhibitors: Pharmacologic aspects and clinical implications for treatment of major depressive disorder and associated painful physical symptoms","volume":"2","author":"Alev","year":"2013","journal-title":"Open J Depression"},{"key":"10.1016\/j.sxmr.2018.12.003_bib32","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1586\/14737175.2.6.849","article-title":"SNRIs: Mechanism of action and clinical features","volume":"2","author":"Lambert","year":"2002","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.sxmr.2018.12.003_bib33","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1017\/S1092852900024020","article-title":"Mechanism of action of trazodone: A multifunctional drug","volume":"14","author":"Stahl","year":"2009","journal-title":"CNS Spectr"},{"key":"10.1016\/j.sxmr.2018.12.003_bib34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","article-title":"Rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"Fagiolini","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sxmr.2018.12.003_bib35","first-page":"28","article-title":"Vilazodone HCl (Viibryd): A serotonin partial agonist and reuptake inhibitor for the treatment of major depressive disorder","volume":"37","author":"Cruz","year":"2012","journal-title":"P\u00a0T"},{"key":"10.1016\/j.sxmr.2018.12.003_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A\u00a0review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Rev"},{"issue":"Suppl 4","key":"10.1016\/j.sxmr.2018.12.003_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199512004-00004","article-title":"The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission","volume":"10","author":"de Boer","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib38","first-page":"36","article-title":"Vortioxetine (brintellix): A new serotonergic antidepressant","volume":"40","author":"D'Agostino","year":"2015","journal-title":"P\u00a0T"},{"key":"10.1016\/j.sxmr.2018.12.003_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S1092852915000139","article-title":"Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): Enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors)","volume":"20","author":"Stahl","year":"2015","journal-title":"CNS Spectr"},{"key":"10.1016\/j.sxmr.2018.12.003_bib40","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/archneur.59.7.1084","article-title":"Mechanisms of action of the 5-HT1B\/1D receptor agonists","volume":"59","author":"Tepper","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib41","first-page":"e631","article-title":"Self-reported alcohol use and hypotension-and-syncope-related adverse events in flibanserin-treated premenopausal women with hypoactive sexual desire disorder","volume":"195","author":"Apfel","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib42","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/jcpt.12563","article-title":"The pharmacodynamic effects of combined administration of flibanserin and alcohol","volume":"42","author":"Stevens","year":"2017","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"Suppl 1","key":"10.1016\/j.sxmr.2018.12.003_bib43","first-page":"15","article-title":"Study on performance and alcohol interaction with the antidepressant fluoxetine","volume":"4","author":"Schaffler","year":"1989","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib44","first-page":"101","article-title":"The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly","volume":"7","author":"Kerr","year":"1992","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib45","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/j.1552-4604.1997.tb04290.x","article-title":"Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol","volume":"37","author":"Troy","year":"1997","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib46","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40262-016-0389-0","article-title":"Lack of effect of vortioxetine on the pharmacokinetics and pharmacodynamics of ethanol, diazepam, and lithium","volume":"55","author":"Chen","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.sxmr.2018.12.003_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152707779940835","article-title":"Effects of psychiatric medications on sleep and sleep disorders","volume":"6","author":"DeMartinis","year":"2007","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.sxmr.2018.12.003_bib48","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.sxmr.2017.05.003","article-title":"Flibanserin efficacy and safety in premenopausal women with generalized acquired hypoactive sexual desire disorder","volume":"5","author":"Fisher","year":"2017","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.sxmr.2018.12.003_bib49","doi-asserted-by":"crossref","first-page":"e2603","DOI":"10.1002\/hup.2603","article-title":"Next-day residual effects of flibanserin on simulated driving performance in premenopausal women","volume":"32","author":"Kay","year":"2017","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/PCC.v03n0105","article-title":"SSRI antidepressant medications: Adverse effects and tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"Suppl 4","key":"10.1016\/j.sxmr.2018.12.003_bib51","first-page":"25","article-title":"Serotonin norepinephrine reuptake inhibitors: Similarities and differences","volume":"16","author":"Shelton","year":"2009","journal-title":"Prim Psychiatry"},{"key":"10.1016\/j.sxmr.2018.12.003_bib52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181a5233f","article-title":"Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis","volume":"29","author":"Serretti","year":"2009","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.jcp.0000125686.20338.c1","article-title":"Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women","volume":"24","author":"Segraves","year":"2004","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib55","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/009262301750257155","article-title":"Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women","volume":"27","author":"Segraves","year":"2001","journal-title":"J\u00a0Sex Marital Ther"},{"key":"10.1016\/j.sxmr.2018.12.003_bib56","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1080\/14656566.2016.1198776","article-title":"Managing comorbid obesity and depression through clinical pharmacotherapies","volume":"17","author":"McElroy","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.sxmr.2018.12.003_bib57","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1089\/jwh.2016.6230","article-title":"Effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with hypoactive sexual desire disorder: A post hoc analysis","volume":"26","author":"Kornstein","year":"2017","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.sxmr.2018.12.003_bib58","author":"Winokur"},{"key":"10.1016\/j.sxmr.2018.12.003_bib59","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/JCP.0b013e31820ebd2c","article-title":"Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication","volume":"31","author":"McClintock","year":"2011","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.sxmr.2018.12.003_bib60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/NSS.S6849","article-title":"Role of 5-HT2A receptor antagonists in the treatment of insomnia","volume":"2","author":"Vanover","year":"2010","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.sxmr.2018.12.003_bib61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuropharm.2012.12.008","article-title":"Further evidence for the sleep-promoting effects of 5-HT2A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats","volume":"70","author":"Griebel","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.sxmr.2018.12.003_bib62","first-page":"43","article-title":"Safety of flibanserin in women treated with antidepressants: A randomized, placebo-controlled study","volume":"15","author":"Clayton","year":"2018","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.12.003_bib63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14740338.2.2.123","article-title":"Safety profile of the triptans","volume":"2","author":"Tepper","year":"2003","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 1","key":"10.1016\/j.sxmr.2018.12.003_bib64","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1111\/j.1526-4610.2004.04105.x","article-title":"Cardiovascular tolerability and safety of triptans: A review of clinical data","volume":"44","author":"Dodick","year":"2004","journal-title":"Headache"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205005211830146X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205005211830146X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T19:37:19Z","timestamp":1672774639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205005211830146X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S205005211830146X"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2018.12.003","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Flibanserin Safety: Comparison with Other Serotonergic Medications","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2018.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}